Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2023 (2023-06-30): -146.17%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$53.12M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$52.60M
Return on Equity (ROE)
-27.93%
TTM Avg
-11.97%
3Y Avg
0.83%
5Y Avg
3.58%
Market Cap
$53.71M
Return on Equity (ROE)
-76.82%
TTM Avg
-798.41%
3Y Avg
-485.96%
5Y Avg
-324.45%
Market Cap
$51.98M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
Market Cap
$54.46M
Return on Equity (ROE)
-60.85%
TTM Avg
-77.57%
3Y Avg
-56.89%
5Y Avg
-53.13%
Market Cap
$51.43M
Return on Equity (ROE)
-36.94%
TTM Avg
-31.55%
3Y Avg
-37.51%
5Y Avg
-20.44%
Market Cap
$50.99M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$50.66M
Return on Equity (ROE)
-57.10%
TTM Avg
-36.66%
3Y Avg
-227.16%
5Y Avg
-314.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spectral AI, Inc. (MDAI) | $52.99M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.12M | -36114.03% | -31.09% | -15.54% | -12.44% |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | -27.93% | -11.97% | 0.83% | 3.58% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.71M | -76.82% | -798.41% | -485.96% | -324.45% |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | -278.89% | -162.92% | 25.71% | 0.37% |
| Aldeyra The (ALDX)vs › | $54.46M | -60.85% | -77.57% | -56.89% | -53.13% |
| ImageneBio Inc (IMA)vs › | $51.43M | -36.94% | -31.55% | -37.51% | -20.44% |
| Envoy Medical, Inc. (COCH)vs › | $50.99M | -708.48% | 156.13% | 510.26% | 342.91% |
| Tenax Therapeutics, Inc. (TENX)vs › | $50.66M | -57.10% | -36.66% | -227.16% | -314.45% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.00M | N/A | 31.64% | 119.26% | -26.51% |
ROE
N/A
ROA
-54.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-06-30 | -146.17% |
| 2023-03-31 | -68.99% |
| 2022-12-31 | -24.27% |
